Analysis and interpretation of the issues facing Pharma: healthcare policy, public opinion, social trends, globalization, and more.
|
September 1, 2011
Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
|
September 1, 2011
By:
William Looney
Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.
|
September 1, 2011
By:
Dr. Jill Conner
Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs.
|
August 1, 2011
By:
Reflector
HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.
|
August 1, 2011
By:
Joe Dysart
Social media now gives companies a plethora of creative ways to digitally spread recent company news and keep customers informed
|
May 1, 2011
By:
Julian Upton
The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance
|
|
April 1, 2011
GSK's Deirdre Connelly puts the focus on four steps to cement a new compliance culture
|
September 1, 2008
The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains
|
June 1, 2008
By:
Humphrey Taylor
This time, powerful interest groups (like pharma) that sank the Clinton healthcare bill are on the side of change
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
